Get Ready for the Latest NNI-362 Phase1a Data on Alzheimer’s Disease at CTAD 2022 with Neuronascent!
Exciting News from Neuronascent Inc.! Neuronascent to Present Further NNI-362 Phase1a Data at CTAD 2022 for Alzheimer’s Disease ROCKVILLE, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) — Neuronascent Inc., today announced its abstract entitled “Reduction of plasma p-Tau181 from a Phase 1a Randomized Trial of NNI-362 in a healthy aged population consistent with amelioration of tau…